Publications by authors named "M Hoopmann"
Article Synopsis
- This study identifies the formation of covalent protein adducts from drug metabolism as significant risk factors for adverse drug reactions and cytochrome P450 enzyme inactivation.
- It introduces a novel liquid chromatography with tandem mass spectrometry (LC-MS/MS) approach to detect low abundance drug-protein adducts in human liver microsomes, using raloxifene as a model.
- The findings reveal adducts in multiple proteins, including CYP enzymes, and suggest that some adducts may be harmless, providing a framework for better understanding the human adductome related to drug exposure.
This extensive AWMF 085-002 S2e-guideline "First Trimester Diagnosis and Therapy @ 11 - 13 of Gestation" has systematically analyzed high-quality studies and publications and the existing evidence (evidence tables) and produced recommendations (level of recommendation, level of evidence, strength of consensus). This guideline deals with the following topics in the context of the 11 - 13 weeks scan: the legal basis, screening for anatomical malformations, screening for chromosomal defects, quality assessment and audit, screening for preeclampsia and FGR, screening for preterm birth, screening for abnormally invasive placenta (AIP) and placenta accreta spectrum (PAS), screening for velamentous cord insertion and vasa praevia, screening for diabetes mellitus and LGA. Screening for complications of pregnancy can best be carried out @ 11 - 13 weeks of gestation.
View Article and Find Full Text PDFArticle Synopsis
- The AWMF 085-002 S2e-guideline provides detailed recommendations based on high-quality studies for screening and managing pregnancy complications during the 11-13 weeks of gestation scan.
- Key topics include screening for anatomical malformations, chromosomal defects, preeclampsia, and other conditions, with solutions for identifying many issues already in place.
- While some complications can be effectively screened and managed in early pregnancy, challenges remain in identifying disorders related to glucose metabolism and preterm birth, making early detection crucial for better outcomes in pregnancy management.